The 2020 Nobel Prize in Chemistry was awarded to Jennifer Doudna and Emmanuelle Charpentier for their fundamental contribution to the discovery of an effective method of genetic editing, i.e. a precision intervention that allows the introduction of desired modifications within DNA in simple, effective, fast and economical way.
The technology developed, called CRISPR/Cas9, represents a true revolution for biomedical research, since it also allows correcting pathological mutations in a specific way.
Often in science, researchers draw inspiration from nature: CRISPR/Cas9 is no exception, being borrowed from bacteria.
In nature, there have always been preys and predators. In the microscopic world of bacteria, predators, or rather invaders, are represented by bacteriophages: they are viruses that attack bacteria, into which they inject their own genetic material to start replication.
To defend themselves against such unwanted attack, bacteria have developed an ingenious system: extremely precise molecular “scissors” that cut the invader’s DNA and inactivate it, thus preventing infection.
Illustration showing the infection of a bacterium by some bacteriophages. The bacteriophages (in green) “dock” to the bacterial membrane (in orange) and inject their own nucleic acid into it. To defend itself, the bacterium has developed the CRISPR/Cas9 system, which cuts the nucleic acid of the bacteriophage in specific spots.
Even more surprising, through the CRISPR/Cas9 system, bacteria are able to genetically memorize the infections already occurred, thus allowing them to respond promptly to a possible second encounter with the pathogen and to pass this response on to their progeny.
The San Raffaele University's Master's Degree Course in Biotechnology offers a solid theoretical preparation combined with intensive training in the research laboratories of San Raffaele. Find out more
CRISPR/Cas9 (sometimes called just CRISPR) is a complex made up of two parts, which together have the function of identifying the desired spot on the target DNA and cutting it.
Illustrative scheme of the mechanism of action of CRISPR/Cas9. 1) At first, the CRISPR/Cas9 complex is assembled, consisting of the specific guide RNA for the sequence to be cut and the Cas9 nuclease. 2) The guide RNA works as an anchor, stopping Cas9 exactly on the spot of the target DNA where the cut is to be made. Cas9 introduces a break on the DNA double helix. 3) DNA can undergo repair by the cell’s natural mechanisms or be corrected with new genetic information.
In particular:
CRISPR is involved in the recognition of the sequences to be cut. This recognition is absolutely specific and takes place thanks to a special RNA molecule, called “guide RNA” (whose sequence is complementary to that of the site to be cut on the DNA), which can be easily modified in the laboratory. As the name implies, the guide RNA “orients” Cas9, the other component of the complex, indicating where to make the break.
Cas (followed by a number, usually 9) is a nuclease, i.e. an enzyme that cuts DNA, and is in fact responsible for cutting the target molecule. Once associated with Cas9, the guide RNA acts as a kind of “anchor”, stopping Cas9 on the designated DNA sequence. Cas9, whose name stands for CRISPR-associated*, introduces a double helix break at the chosen site, and can be programmed to make specific changes to a cell’s genome.
Are you looking for an excellent interdisciplinary training in the field of Molecular Medicine? The San Raffaele University's Dctorate, entirely in English, is perfect for you.
Once cut, the DNA can be adjusted by the cell’s natural repair mechanisms; alternatively, through suitable measures, it is possible to eliminate harmful DNA sequences from the target genome or to replace sequences, for example by correcting mutations causing diseases.
Exactly, why is CRISPR/Cas9 such a revolutionary technique? Why did it deserve the Nobel Prize? What is its potential? We asked Dr. Angelo Lombardo, Group leader of the “Epigenetic regulation and targeted genome editing” Unit of the IRCSS San Raffaele Hospital and UniSR researcher.
CRISPR/Cas9 is a very versatile gene editing system. The CRISPR/Cas9 complex induces a break in the DNA double helix, thus activating highly conserved repair processes that can eventually lead to the inactivation of the targeted gene.
These processes can also be exploited to insert new genetic information within the CRISPR/Cas9 target site, or to correct pathological mutations. Once modified, CRISPR/Cas9 can also be used to deliver factors on DNA that activate or inhibit gene expression.
On the left, the structure of the Cas9 nuclease (in pink) captured in its active state: in red, the guide RNA necessary for the activity of the enzyme. To such strand, another DNA strand (in green) is paired up, which is unwound and cut, leaving a paired fragment (in light blue) downstream of the cleavage point. In the figure on the right a part of the Cas9 protein (the HNH domain, responsible for part of the Cas9 activity) has been excluded to allow us to appreciate how the target DNA and the guide RNA form a hybrid double helix and favor the opening of the DNA, allowing it to be cut at a specific spot. Courtesy of Dr. Massimo Degano, Group leader of the Biocrystallography Unit of the IRCCS San Raffaele Hospital.
The advent of CRISPR/Cas9 has revolutionized biomedical research, making gene editing a quick and easy procedure. From a clinical point of view, the precision of this new form of molecular medicine opens up interesting perspectives for the treatment of many diseases.
Finally, with the Nobel Prize, a long and virtuous research path was awarded, which culminated in the molecular characterization of the mechanism of action of CRISPR/Cas9 and the first demonstrations of how this system can be used for targeted gene editing.
The CRISPR/Cas9 system is extremely versatile and easy to use, making it ideal for many applications. These range from biomedical research to therapy and diagnostics, from the generation of animal disease models to targeted gene modification in agronomy and zoology.
Before CRISPR/Cas9 (or B.C., Before CRISPR) there were other systems of targeted gene editing. Among the most efficient it is worth mentioning zinc finger nucleases (or ZFN) and TALEN, two genetic editing systems still in use and already in the clinic.
Unlike CRISPR/Cas9, ZFNs and TALENs are more complex to program, and therefore less widespread. However, their use largely overlaps with that of CRISPR/Cas9. The ten-year research and clinical experience gained with the ZFNs and TALENs has allowed a rapid development of CRISPR/Cas9.
San Raffaele Institute was one of the pioneers of targeted gene editing. To date, CRISPR/Cas9 has become common practice in the Institute’s biomedical research, and several laboratories are evaluating its therapeutic potential. In particular, preclinical studies show encouraging results in the treatment of numerous rare genetic diseases and in cancer immunotherapy. Given the potential of CRISPR/Cas9, it is plausible that this promising technology will have many other therapeutic applications.
*CRISPR is an acronym for “Clustered regularly interspaced short palindromic repeats”.